Wegovy’s cash price drops to $349, with a lower price for the first two months
Novo cut its self-pay price again and added an introductory offer for the two lowest doses, a week after the White House deal.
Who feels it
-
Patients
Rethink
The cash price is now about a quarter of the list price; check whether the intro offer fits your dose.
-
Pharmacies
Adjust
More cash patients may come to retail pharmacies that carry the offer.
-
Sellers
Adjust
Cash prices are now a direct race between the two makers.
-
Prescribers
Worth knowing
Lower cash prices make it easier to keep patients on treatment between coverage changes.
-
Payers
Worth knowing
A lower cash anchor puts pressure on what plans pay through rebates.
The new price
Novo Nordisk lowered the self-pay price of Wegovy and Ozempic to $349 a month. New patients could get the two lowest Wegovy doses for $199 a month for the first two months.
Why the timing
The cut came days after the White House deal set lower public prices. It also answered Lilly’s cash vials, which had been cheaper for starting doses.
How far prices have moved
| Date | Wegovy cash price |
|---|---|
| Before March 2025 | No cash channel (list about $1,349) |
| March 2025 | $499 |
| November 2025 | $349 |
The point
Cash prices for these drugs fell by about three quarters in under a year. For people without coverage, that is the most important change of 2025.
Source Novo Nordisk press release, November 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
